Astrana Health opened lower at $32.59, compared with its previous close of $32.94. In the last trading session, the stock traded between $31.25 and $33.02. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Astrana Health is now worth
$ 74.35
Resulting in a loss of
$ 25.65 (25.65%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-1.13 (-3.42%)
Day High
$33.02
Day Low
$31.25
Day Open
$32.59
Prev Close
$32.94
Volume
2,45,980
1W Return
-19.74%
1M Return
-17.28%
3M Return
-7.76%
6M Return
-16.21%
1Y Return
33.68%
Market Cap ($ Mn)
1,578
PE Ratio
45.73
PB Ratio
2.25
PEG Ratio
5.51
ROE
3.19%
ROCE
6.29%
EPS (TTM)
$0.26
1 Week
-19.74%
1 Month
-17.28%
3 Months
-7.76%
6 Months
-16.21%
9 Months
67.18%
Astrana Health Q3FY26 Results: Revenue up 7% YoY to $1.02 billion
Record Q3 revenue of $1.02 billion, up 7% YoY, driven by organic growth. Adjusted EBITDA rose 13% YoY to $77.2 million, near the high end of guidance. Net leverage reduced to 2.2x, ahead of deleveraging targets post-Prospect acquisition. Full-risk arrangements projected to reach 82% of capitation revenue by year-end. Maintained full-year adjusted EBITDA outlook of $261-$274 million.
7 days agoPomerantz investigates Astrana Health over securities fraud claims
Pomerantz LLP investigates Astrana Health for potential securities fraud. Short report alleges growth driven by acquisitions not organic expansion. Concerns raised over $545 million related-party loan and Medicare exposure. Stock fell 9.02% to $34.30 following report publication on September 17, 2026.
1mo agoVerda Healthcare signs multi-state partnership with AstranaCare
Verda Healthcare partners with AstranaCare Partners in Arizona and Texas. Partnership targets Pan-Asian, Hispanic, and Arab American communities. Astrana Health manages over 1.6 million lives across 20,000+ providers. Verda offers MA and C-SNP plans for underserved counties.
1mo agoPomerantz probes Astrana Health over short report allegations
Pomerantz LLP investigates Astrana Health for securities fraud following a short report. Glass House Research alleged aggressive acquisitions and a $545 million related-party loan. Stock fell 9.02% to $34.30 per share after the report's publication. Separate investigation by AWKO Law LLP continues regarding a September 2026 data breach.
1mo agoAstrana Health FY26 Results: Sales guidance affirmed at $3.800B-$4.100B
Astrana Health affirms FY26 sales guidance of $3.800 billion to $4.100 billion. The reaffirmed range is below the $4.004 billion analyst estimate. No change was made to the previously issued revenue outlook.
1mo agoLowey Dannenberg probes Astrana Health after short-seller report
Lowey Dannenberg P.C. is investigating Astrana Health for potential federal securities law violations. A short-seller report alleged growth relies on acquisitions rather than organic expansion. Astrana stock fell 9.02% following the report, dropping $3.40 per share. Concerns raised include a $545 million related-party loan and 2027 Medicare regulatory risks.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $506.04 | +0.32% | $1,05,708.21M | 14.01 | |
| $304.77 | -0.26% | $49,345.01M | 45.36 | |
| $292.97 | +0.93% | $23,316.90M | 10.31 | |
| $72.62 | +0.18% | $14,450.29M | 52.31 | |
| $79.43 | -1.38% | $14,087.55M | - | |
| $142.24 | -0.19% | $13,957.16M | 20.21 | |
| $22.22 | -2.29% | $11,935.03M | 11.93 | |
| $183.50 | +2.35% | $11,542.15M | 15.26 | |
| $186.19 | +0.59% | $10,862.51M | 27.11 | |
| $196.77 | +0.70% | $10,170.65M | 7.00 | |
| $103.03 | -0.49% | $8,522.13M | 34.79 | |
| $50.06 | +1.96% | $7,945.72M | 25.00 |
An investment of $100 made 3 years ago in Astrana Health is now worth
$ 74.35
Resulting in a loss of
$ 25.65 (25.65%)
Note: Past profits do not guarantee future returns.
